Fiche publication
Date publication
novembre 2025
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HERVIEU Alice
Tous les auteurs :
Borcoman E, Hervieu A, Cropet C, Coquan E, Guigay J, Rolland F, Bernadach M, Charafe E, Legrand F, Dassé E, Le Tourneau C, Gonçalves A
Lien Pubmed
Résumé
Treatment options for advanced solid tumors are limited. In recent years, anti-programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy as monotherapy has shown significant efficacy, albeit in a limited subset of patients. In the MOVIE trial, metronomic chemotherapy was combined with two immune checkpoint inhibitors (ICIs) to improve clinical outcomes in patients with advanced solid tumors.
Mots clés
anti-CTLA-4, anti-PD-1/PD-L1, head and neck squamous cell carcinoma (HNSCC), immune checkpoint inhibitor (ICI), metronomic chemotherapy (MC)
Référence
ESMO Open. 2025 11 5;10(11):105840
